Rapamycin and Alzheimer's disease: Time for a clinical trial?

Matt Kaeberlein, Veronica Galvan Hart

Research output: Contribution to journalReview article

10 Scopus citations

Abstract

The drug rapamycin has beneficial effects in a number of animal models of neurodegeneration and aging including mouse models of Alzheimer's disease. Despite its compelling preclinical record, no clinical trials have tested rapamycin or other mTOR inhibitors in patients with Alzheimer's disease. We argue that such clinical trials should be undertaken.

Original languageEnglish (US)
Article numbereaar4289
JournalScience Translational Medicine
Volume11
Issue number476
DOIs
StatePublished - Jan 23 2019

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this